for the ASTER Trial Investigators IMPORTANCE The benefits of endovascular revascularization using the contact aspiration technique vs the stent retriever technique in patients with acute ischemic stroke remain uncertain because of lack of evidence from randomized trials.
A fter recent reports from 6 randomized clinical trials (RCTs) demonstrated the superiority of mechanical thrombectomy over standard medical management alone, research priorities shifted toward reducing time to revascularization, optimizing imaging methods for patient selection, and evaluating new thrombectomy devices.
1-3 Because stent retriever techniques were used predominantly in these trials, questions remain regarding the safety and efficacy of aspiration thrombectomy techniques as a first-line therapy. A direct aspiration first-pass technique (ADAPT), or contact aspiration, involves the first-line use of aspiration through a largebore catheter, 4-8 then adding a stent retriever if needed. In cases in which aspiration alone is not successful in removing the thrombus, the large-bore aspiration catheter provides the additional benefit of offering access for a stent retriever.
Contact aspiration has not been demonstrated to be superior or noninferior to the stent retriever technique. Nevertheless, aspiration has gained growing acceptance as it is thought to facilitate revascularization quickly and potentially at a lower cost. 9 Controversies about the relevance of the technique have arisen in rare cases of aspiration component failure because of concerns that it might result in a delay in revascularization that could have been avoided by using the stent retriever technique as first-line endovascular therapy. Although no randomized trials have studied aspiration vs the stent retriever technique to date, some retrospective studies have reported increased successful revascularization rates when using contact aspiration as first-line endovascular treatment. 7, 10 Additional insights through RCTs are needed to identify which patients may benefit from this novel technique. The Contact Aspiration vs Stent Retriever for Successful Revascularization (ASTER) trial aimed to compare the efficacy and adverse events of first-line neurothrombectomy using the contact aspiration technique vs the standard stent retriever technique.
Methods
The study protocol and the consent form were approved by the Comité de Protection des Personnes Ile de France VI (ID 2015-A00830-49) . The details of the trial protocol were published previously 11 (available in Supplement 1).
Trial Design
This trial was a randomized, multicenter, open-label, blinded end-point clinical trial. It was an investigator-initiated trial designed to assess the effect of the first-line strategy for mechanical thrombectomy (contact aspiration vs stent retriever) on revascularization rates at the end of all endovascular procedures.
Patients were recruited at 8 high-volume, comprehensive stroke centers in France, all of which regularly perform both types of techniques. The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice.
12 Data collection during the study was facilitated with an electronic case report form developed using Clinsight software (ENNOV).
According to French laws, oral informed consent was sought from patients if their level of consciousness was sufficient, or else from a relative. This study operated under an emergency inclusion protocol because of the nature of the condition.
Patient Population
This study enrolled adults admitted with suspected ischemic stroke secondary to occlusion of the anterior circulation within 6 hours of onset of symptoms. Patients were required to have imaging evidence of occlusion of the intracranial internal carotid artery or the M1 or M2 branches of the middle cerebral artery. Use of intravenous (IV) thrombolysis treatment was permitted. Key exclusion criteria included cerebral infarction of the posterior circulation, occlusion of the cervical carotid artery, and prestroke modified Rankin Scale (mRS) score greater than 3.
Randomization
Immediately after baseline brain imaging and prior to the endovascular procedure, patients were randomly allocated in a 1:1 fashion to undergo either contact aspiration (intervention) or stent retriever (control) thrombectomy as the firstline intervention. The randomization sequence was provided by an independent statistician (who did not take part in assessing the patients at any point in the study) using computergenerated random numbers with block sizes of 4 and stratification by center and IV tissue plasminogen activator (tPA) treatment. The block size information was not specified in the protocol to ensure that vascular neurologists and interventional neuroradiologists were not able to anticipate treatment group assignment. The randomization sequence was implemented in the electronic case report form system to ensure a centralized real-time randomization procedure. Patients were enrolled and randomized by vascular neurologists and interventional neuroradiologists.
Interventions
In line with the recommendations of the American Stroke Association and European Stroke Organization, 3,13 enrolled patients received IV thrombolysis (if eligible) and were then transferred to the angiographic suite for urgent thrombectomy.
Patients underwent their assigned endovascular procedure (contact aspiration or stent retriever) under general anesthesia or conscious sedation. Operators were required to perform at least 3 attempts at revascularization using the assigned endovascular technique before switching to another endovascular procedure (rescue therapy) if needed and in accordance with good practice recommendations. The decisions of whether to use a rescue therapy and which rescue therapy to use were at the discretion of the operator. Permitted rescue techniques were contact aspiration, stent retriever, combined contact aspiration and stent retriever, and angioplasty with or without stenting. Contact aspiration was performed using a long sheath positioned in the distal cervical vasculature using an exchange technique. The technique has been previously reported. 4, [6] [7] [8] 14 A 0.021-to 0.027-in inner lumen microcatheter was advanced up to or past the thrombus over a microwire and then a large-bore aspiration catheter was advanced as close to the proximal aspect of the thrombus as possible. The large-bore aspiration catheter was connected to a source of continuous aspiration, and thrombus aspiration was attempted.
The stent retriever technique used was in accordance with the European Conformity marked device instructions for use. A large-bore balloon guide catheter was positioned in the cervical internal carotid artery. A delivery microcatheter was navigated over a microwire into the occluded artery, and the stent retriever was deployed across the occlusion. During stent retriever removal, the proximal vessel was occluded by inflation of the balloon guide catheter. The Solitaire and Trevo stent retriever devices were most commonly used.
Outcomes Primary Outcome
The primary outcome was the percentage of patients with successful revascularization defined as a modified Thrombolysis in Cerebral Infarction (mTICI) score of 2b or 3 15 at the end of angiography after all endovascular treatments.
Secondary Outcomes
The secondary technical efficacy outcomes included the percentage of patients with successful revascularization (separately defined as mTICI score of 2b/3, mTICI score of 2c/3, or mTICI score of 3) at the end of the first-line procedure, the percentage of patients with successful revascularization (separately defined as mTICI score of 2c/3 or mTICI score of 3) at the end of all procedures, and the time from arterial puncture to successful revascularization (defined as mTICI score of 2b/3). The secondary clinical efficacy outcomes were degree of disability assessed by overall distribution of the mRS score at 90 days (shift analysis combining scores of 5 and 6), 16 functional independence as defined by a 90-day mRS score of 2 or lower, change in National Institutes of Health Stroke Scale (NIHSS) score at 24 hours, and death due to any cause at 90 days. Adverse events included procedure-related serious adverse events (arterial perforation, arterial dissection, embolization in a new vascular territory, subarachnoid hemorrhage, vasospasm), intracranial hemorrhage on imaging at 24 hours according to the European Cooperative Acute Stroke Study 3 classification, and symptomatic intracranial hemorrhage at 24 hours, defined as any intracranial hemorrhage, including intracerebral, subarachnoid, and intraventricular hemorrhages, visualized on follow-up imaging and associated with a 4-point or greater worsening on the NIHSS score or that resulted in death.
A cost-effectiveness analysis was prespecified as a secondary end point and is ongoing.
Blinding
For the primary outcome, 2 independent assessors at a central imaging core laboratory not involved in patient management determined the mTICI score and collateral status. In cases of disagreement between the 2 assessors, a centralized neurointerventionalist reviewed angiograms and decided on the primary end-point value. All neuroimaging readings including determination of site of arterial occlusion, clot burden score, and hemorrhagic transformation were performed at the imaging core laboratory and blinded to procedure allocation. Serious adverse events and procedure-related complications were adjudicated by 3 members of the data and safety monitoring board blinded to treatment group. The 90-day mRS score was assessed by trained research nurses unaware of the group assignments during face-to-face interviews or via telephone conversations. The NIHSS score at 24 hours was assessed by the treating physician, who was not blinded to the group assignments.
Statistical Analysis
The study was designed to have a statistical power of 90% with a 2-sided α=.05 to demonstrate the superiority of first-line contact aspiration over stent retriever in achieving the primary outcome. The sample size was calculated based on an expected rate of successful revascularization of 70% in patients treated with stent retrievers 2,7 and assuming an absolute increase in successful revascularization of 15% with the contact aspiration strategy. This difference was based on published data on contact aspiration and on 2 nonrandomized studies comparing contact aspiration with stent retriever as first-line endovascular therapy. [6] [7] [8] 10, 17 Assuming a rate of spontaneous revascularization and catheterization failures of 15%, 18 a total of 380 patients (190 per group) was required. Analyses were performed on all randomized patients in their assigned group according to the intention-to-treat principle. Categorical variables are reported as frequencies and percentages. Quantitative variables are reported as mean (standard deviation) or median (interquartile range [IQR] ) for nonnormal distribution. Normality of distributions was assessed graphically and by using the Shapiro-Wilk test.
Rates of the primary outcome were compared between the 2 groups using a mixed logistic regression model adjusting for the randomization stratification variables by including IV thrombolysis as a fixed effect and center as a random effect. From this model, we derived an effect size measure, adjusted odds ratio (OR), and 95% confidence interval around the OR for contact aspiration relative to stent retriever. We also calculated absolute and relative risk differences from the marginal probabilities of successful revascularization, estimated by a mixed logistic regression model using the method described by Austin. 19 For the primary outcome, missing values due to groin access failure (n = 4) were treated as failures (mTICI score of 0), and in cases of unavailable or poor-quality core laboratory images (n = 20), mTICI scores from the study site evaluation were used. A sensitivity analysis was conducted in the per-protocol population, which was defined as all patients who received at least 3 attempts at successful revascularization with the assigned first-line endovascular treatment. An unplanned sensitivity analysis was conducted using the mTICI scores as graded by the study site for all patients. Treatment effect modification on the primary outcome was explored in prespecified subgroups: IV thrombolysis (yes vs no), location of thrombus (intracranial internal carotid artery vs M1 branch of the middle cerebral artery vs M2 branch of the middle cerebral artery) based on vascular imaging at time of admission, and clot burden score (<6 vs ≥6). An unplanned subgroup analysis was also conducted according to clot length (<8 vs ≥8 mm). Treatment effect size heterogeneity across the subgroups was tested by including the corresponding multiplicative interaction term into the mixed logistic regression model.
Further details on statistical analysis for secondary outcomes are available in the eAppendix in Supplement 2). All statistical tests were 2-sided, and P < .05 was considered statistically significant. No adjustment for multiple testing was applied and thus, all secondary objectives are considered exploratory. Data were analyzed using SAS software version 9.4 (SAS Institute Inc).
Results

Randomization and Baseline Characteristics
Between October 2015 and October 2016, a total of 381 patients (mean age, 69.9 [SD, 14.3] years; 207 men [54.3%]) were included in the intention-to-treat analysis (Figure 1) . One hundred ninety-two patients were randomized to first-line treatment with contact aspiration and 189 to first-line treatment with a stent retriever. Details of device use are available in the eTable in Supplement 2.
Among the 381 patients enrolled, the mean baseline NIHSS score was 16.2 (SD, 6.2) and the median time from symptom onset to arterial puncture was 227 minutes (IQR, . The 2 groups were well balanced regarding most of the a There were 13 missing values (6 in the contact aspiration group).
b The NIHSS classifies neurological deficit from 0 (no deficit) to 42 (most severe). There were 3 missing values (1 in the contact aspiration group).
c Modified Rankin Scale score range: 0 (symptom free) to 6 (dead).
d Alberta Stroke Program Early Computed Tomography Score (ASPECTS) measures the extension of stroke, with a score range of 0 to 10 (higher scores indicating fewer early ischemic changes). There were 5 missing values (1 in the contact aspiration group).
e Assessed angiographically by an independent core laboratory (not available for spontaneous clot lysis, n = 27, or groin access failure, n = 4).
f Tandem lesion involves an occlusion of the internal carotid artery at the bifurcation with an intracranial middle cerebral artery occlusion.
g The clot burden score (range, 0-10; lower score indicates higher clot burden)
is a semiquantitative imaging-based score that assesses the number of arterial segments exhibiting a visible clot, assessed by an independent core laboratory after excluding patients with poor-quality images, incomplete examinations, or nondetected clot (254 assessed values, 129 in the contact aspiration group). h Assessed by an independent core laboratory after excluding patients with poor-quality images, incomplete examinations, or nondetected clot (293 assessed values, 147 in the contact aspiration group). i The arterial occlusion lesion score ranges from 0 to 3 (0 indicates no revascularization of the primary occlusive lesion; 3, complete revascularization). j The collateral score ranges from 0 to 4 (0 indicates poor collateral supply; 4, good collateral supply) via an American Society of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology grading system. A favorable collateral score refers to grade 3-4. k There were 3 missing values (1 in the contact aspiration group).
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Original Investigation Research jama.com (Reprinted) JAMA August 1, 2017 Volume 318, Number 5 447 baseline characteristics, except for age, admission systolic blood pressure, prestroke mRS score, and site of occlusion ( Table 1) . Endovascular techniques were largely standardized (a balloon-guide catheter was used to allow proximal flow arrest during stent retriever removal in 92% of patients treated with the stent retriever technique).
Angiographic Efficacy Outcomes
The primary outcome was assessed by the core laboratory in 357 patients (93.7%; 181 in the contact aspiration group and 176 in the stent retriever group). The primary efficacy outcome was not significantly different in the contact aspiration vs stent retriever groups (85.4% [n = 164] vs 83.1% [n = 157]; OR, 1.20; 95% CI, 0.68-2.10; P = .53) ( Table 2 ). The corresponding risk difference was 2.4% (95% CI, −5.4% to 9.7%). The distribution of mTICI scores after all endovascular procedures is shown in Figure 2A . There were no significant between-group differences in the primary outcome in sensitivity analyses restricted to the per-protocol population or when successful revascularization was defined as mTICI score of 3 or mTICI score of 2c/3 (Table 2) .
After first-line strategy only, there were no significant differences between groups in revascularization rates (Figure 2B c Eleven patients in the contact aspiration group and 13 in the stent retriever group were not assessed by the core laboratory because of groin access failure or unavailable or poor-quality images.
d mTICI score: 0, no perfusion or anterograde flow beyond site of occlusion; 1, penetration but not perfusion (contrast penetration exists past the initial obstruction but with minimal filling of the normal territory); 2, incomplete perfusion wherein the contrast passes the occlusion and opacifies the distal arterial bed but rate of entry or clearance from the bed is slower or incomplete compared with noninvolved territories; 2a, some perfusion with distal branch filling of <50% of territory visualized; 2b, substantial perfusion with distal branch filling of Ն50% of territory visualized; 2c, near-complete perfusion except for slow flow in a few distal cortical vessels or presence of small distal cortical emboli; and 3, complete perfusion with normal filling of all distal branches.
e Prespecified as the primary efficacy analysis.
f Unplanned sensitivity analysis.
g There were 23 missing 24-hour NIHSS values (12 in the contact aspiration group).
h Mean change (95% CI) adjusted on baseline NIHSS score.
i Mean risk difference adjusted on baseline NIHSS score.
j Defined as a modified Rankin Scale score Յ2.
k Common odds ratio of improvement of 1 point in modified Rankin Scale score.
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and Table 2 ). Rescue treatment after first-line strategy occurred in 63 patients (32.8%) in the contact aspiration group and 45 patients (23.8%) in the stent retriever group, with no significant difference between groups (OR, 1.57; 95% CI, 0.99-2.47; P = .05). Among the 119 patients (68 contact aspiration and 51 stent retriever) with failure of first-line therapy (defined as mTICI score of 0/1/2a graded at the time of procedure by operator), rescue treatment was used in 57 patients (83.8%) in the contact aspiration group and 42 patients (82.4%) in the stent retriever group (OR, 1.21; 95% CI, 0.43-3.38; P = .72).
There was no significant difference in the total number of revascularization attempts, with a median of 2 (IQR, 1-4; range, 0-11) in the contact aspiration group and 2 (IQR, 1-3; range, 0-15) in the stent retriever group (P = .84).
Among patients reaching the primary outcome, the median time from arterial puncture to revascularization was 38 minutes (IQR, 24-60 minutes) in the contact aspiration group and 45 minutes (IQR, 31-60 minutes) in the stent retriever group (P = .10).
Clinical Efficacy Outcomes
Early improvement in neurological outcomes was not significantly different between the 2 groups, with a mean change in NIHSS score at 24 hours of −4.8 points (95% CI, −6.1 to −3.6) in the contact aspiration group and −5.2 points (95% CI, −6.5 to −3.9) in the stent retriever group (mean difference, 0.38; 95% CI, −1.42 to 2.18; P = .68). Among 363 patients (95.3%) with mRS assessments at 3 months, no significant difference was found in the proportion who were functionally independent (45.3% in the contact aspiration group vs 50.0% in the stent retriever group; OR, 0.83 [95% CI, 0.54-1.26]; P = .38; risk difference, −4.6% [95% CI, −14.7% to 6.1%]) (Table 2 ). There was no significant shift in the mRS distribution in favor of the contact aspiration strategy, with a common OR for a 1-point improvement of 0.76 (95% CI, 0.53-1.10; P = .15) (eFigure 1 in Supplement 2; Table 2 ).
Adverse Events
All-cause mortality at 3 months occurred in 70 patients (19.3%). Intracranial hemorrhage at 24 hours was observed in 87 patients (46.3%) in the contact aspiration group and 85 patients (46.2%) in the stent retriever group; the types of hemorrhage are detailed in Table 3 . Symptomatic intracranial hemorrhage occurred in 10 patients (5.3%) in the contact aspiration group and 12 patients (6.5%) in the stent retriever group. Procedure-related adverse events occurred in 31 patients (16.2%) in the contact aspiration group and 30 patients (15.9%) in the stent retriever group. The most frequent event was subarachnoid hemorrhage (n=26), followed by vasospasm (n = 17), embolization in a new vascular territory (n = 12), arterial perforation (n = 8), and arterial dissection (n = 7). New ischemic stroke in a different vascular territory occurred in 10 patients (5.3%) in the contact aspiration group and 16 (8.5%) in the stent retriever group.
Subgroup Analyses
Prespecified exploratory subgroup analyses (IV tPA treatment, site of occlusion, clot burden score) showed no significant heterogeneity in treatment effect on the primary outcome across the studied subgroups (eFigure 2 in Supplement 2).
Unplanned Analyses
In exploratory analyses of the primary outcome that were not prespecified, there was no heterogeneity of treatment effect Scores indicate the following: 0 (no revascularization), no perfusion or anterograde flow beyond site of occlusion; 1 (minimal revascularization), contrast passes the area of occlusion but fails to opacify the entire cerebral bed distal to the obstruction during angiographic run; 2 (partial revascularization), 2a, partial filling (<50%) of territory visualized, and 2b, partial filling (Ն50%) of territory visualized; 3 (complete revascularization), complete revascularization with normal filling. a Primary outcome.
b Assessed by core laboratory. Missing data due to groin access failure (n = 4) were treated as failures (mTICI score of 0) and missing data due to no core laboratory reading (n = 20 for mTICI score at end of all procedures and n = 22 for mTICI score after first-line procedure) were replaced by the study site evaluation regardless of treatment groups. in a subgroup analysis by clot length and no significant between-group differences in a sensitivity analysis using mTICI scores from local study sites. A significantly shorter time from clot contact to revascularization was observed in the contact aspiration group (median, 13 minutes; IQR, 6-38 minutes) compared with the stent retriever group (median, 22 minutes; IQR, 10-38 minutes; P = .03), but this was not a prespecified outcome and should be considered exploratory.
Discussion
In this multicenter RCT, 381 patients with acute ischemic stroke and large vessel occlusion were randomized to undergo either contact aspiration or stent retriever as first-line endovascular treatment. First-line contact aspiration was not superior to firstline stent retriever in achieving successful revascularization at the end of the endovascular procedure. To our knowledge, this is the first open-label RCT with blinded end-point evaluation to compare first-line contact aspiration vs stent retriever for mechanical thrombectomy in acute ischemic stroke. Patients were enrolled across 8 comprehensive stroke centers, with very few restrictive inclusion criteria in keeping with clinical situations. The use of an independent imaging core laboratory reduced bias in evaluation of the primary outcome, and the short period in which patient enrollment was completed reduced potential bias in a field in which technological progress and refinement evolve rapidly. The endovascular techniques were largely standardized in both groups, patients in the stent retriever group were primarily treated with validated devices, and there were few crossovers (90% of patients received the allocated treatment).
The primary outcome for this study was the difference in revascularization rates after all procedures. Revascularization rate was chosen as the primary outcome because it is a major early indicator of treatment success, has been correlated with good clinical outcome, 15, 20 and has been used as a primary outcome in other stroke trials comparing thrombectomy devices; eg, SWIFT 21 and TREVO2. 22 The primary outcome was assessed at the end of all procedures because the goal of the study was to assess the effect of first-line endovascular strategy on revascularization after the entire procedure rather than to directly compare the contact aspiration and stent retriever techniques when used alone. Successful revascularization was specifically defined as an mTICI score of 2b or 3 in this study because this outcome has been reported to be a predictor of clinical outcome. 20, 23, 24 Theoretically, contact aspiration could result in a higher rate of an mTICI score of 3 compared with stent retriever because use of a stent retriever requires that it be passed through the clot and therefore might result in a higher rate of distal emboli (as was found in an in vitro study 25 ), but there were no significant differences between groups in the secondary outcome of an mTICI score of 3 or in the frequency of embolization to a new vascular territory in this study.
Contact aspiration and stent retriever were never used simultaneously during the first-line strategy, as this was not allowed in the study protocol. However, during rescue therapy, the choice of the technique was left to the discretion of the operator, and there were 2 instances of combined use of contact aspiration plus stent retriever in the contact aspiration group and 8 instances in the stent retriever group. The effect of combining contact aspiration and stent retriever to obtain a better rate of recanalization, especially perfect recanalization, has never been studied in an RCT and is a potential area of future study.
The hypothesis of this trial was that use of first-line contact aspiration would increase the rate of successful revascularization by 15% compared with a first-line stent retriever (superiority design), so, although contact aspiration was not superior to stent retriever in achieving successful recanalization, this study was not designed to claim equivalence or noninferiority of these strategies. Furthermore, although the contact aspiration group did not achieve a 15% increase in successful revascularization, a smaller yet potentially clinically significant difference in revascularization rate cannot be fully excluded.
Regarding secondary clinical outcomes and adverse events, there were no significant differences between groups, although the trial was not powered to assess differences in these e Hemorrhage in <30% of the infarcted area with mild space-occupying effect.
f Hemorrhage in >30% of the infarcted area with significant space-occupying effect.
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outcomes. A retrospective study comparing aspiration and stent retriever techniques reported a lower rate of symptomatic hemorrhages for contact aspiration compared with stent retriever (2.9% for contact aspiration and 5.4% for stent retriever), 7 and retrospective studies have reported low rates of embolization in a new territory (2%) and no incidence of symptomatic intracranial hemorrhage when using contact aspiration. 6, 8 Embolization in a different vascular territory occurred in 3.7% of the contact aspiration group in this study, which is less than the rates of 6% and 5.7% reported in 2 recent retrospective studies. 7, 26 Adverse events in the retrospective analyses were site reported, while in this trial, they were adjudicated in a blinded manner.
Limitations
This study has several limitations. First, the primary end point was technical (ie, successful revascularization after all interventions), which is less relevant than a clinical outcome such as the 90-day mRS score. Second, given its superiority design to detect a 15% difference in the primary end point, this trial was not designed to establish noninferiority between contact aspiration and stent retriever as first-line endovascular strategies and not powered to detect a smaller yet potentially clinically important difference between groups. Third, the use of rescue therapy was at the discretion of the operator and is a potential source of bias, although the rates of rescue therapy were not significantly different between groups overall or among those who experienced failure after first-line thrombectomy. Fourth, participating centers were all highly experienced in performing both endovascular techniques, which may explain the high mTICI 2b/3 score rates in both study groups and may limit the ability to generalize these findings to other comprehensive stroke centers with less experience in these techniques. Fifth, although the 2 groups were well balanced for most of the baseline characteristics, the degree of randomness was limited by using the stratified permuted randomization with fixed blocks of 4 in light of the sample size and number of strata. Sixth, although exploratory subgroup analyses showed no heterogeneity in treatment effect across the studied subgroups for the primary outcome, these results should be interpreted with caution given that the study was not designed to have adequate power for subgroup analyses.
Conclusions
Among patients with ischemic stroke in the anterior circulation undergoing thrombectomy, first-line thrombectomy with contact aspiration vs stent retriever did not result in a higher successful revascularization rate at the end of the procedure.
Role of the Funder/Sponsor:
The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. The study protocol and the form of consent were approved by the CPP (Comité de Protection des Personnes) CLEAN, 2014 ESCAPE, 2015 , SWIFT PRIME, 2015 , EXTEND IA, 2015 . These studies have 24
shown for the first time that mechanical thrombectomy is the reference treatment for cerebral infarction 25 related to proximal cerebral occlusion and results in -35% of severe cerebral infarction disability and 26 decreased mortality. All of these studies used stent retriever thrombectomy devices to achieve 58-72% 27 recanalization (MR CLEAN, 2014 ESCAPE, 2015 .This "recanalization" criterion is of major importance 28 because it largely determines the functional prognosis of patients following cerebral infarction (Khatri, 29 2014) . 30
These results are exciting but we can do even better. Indeed, already new strategies of thrombectomy are 31 available with a particular attraction for ADAPT (A Direct Aspiration first Pass Technic). This technique 32 involves starting the thrombectomy procedure by direct aspiration of the thrombus, using a dedicated 33 suction catheter. This technique provides a high level of endovascular navigability and allows high 34 recanalization rates (> 90%), with low morbidity (Turk A, 2014 and Kowoll 2015) .Indeed, if 35 recanalization is not obtained with the aspiration catheter, the operator can deploy a stent retriever through 36 the suction catheter, combining the interest of both techniques. 37 38
We first performed a comparative observational study between these two strategies among 244 patients in 39 two centers (FOR, and Hôpital Foch) for cerebral infarction related to a proximal occlusion. This is, to 40 date, the largest series of patients with ADAPT as a first line strategy. The complete recanalization rate 41 was 84% with ADAPT versus 68% with a stent retriever (P = 0.006) (Unpublished data, Oral presentation 42 at the European Stroke Organization, April 2015). 43
Our study aims to evaluate in a rigorous way whether the first-line aspiration during thrombectomy in the 44 acute phase of cerebral infarction is of interest to patients in terms of immediate surgical success and 45 prognosis for the patient. The aim is to determine the best thrombectomy strategy to reduce the stroke 46 patient's disability. Indeed, recanalization of the occluded artery is the major prognostic factor associated 47 with patient disability. Currently, stroke affects 1 patient every 4 minutes in France, with each year, 48 approximately 130,000 new patients (prevalence estimated at nearly 800,000 patients, of which 500,000 49 will have sequelae). 50
In 2004, cerebral infarction was the most costly pathology for the health care system in terms of average 51 annual expenditure per patient and the total reimbursement per long-term condition (ALD). With 52 endovascular therapy (mechanical thrombectomy), there are twice as many patients who can live 53 independently after this type of stroke. A retrospective preliminary study suggests that the ADAPT 54 thrombectomy system has a better cost-effectiveness ratio (Turk, AS, 2014) . 55 2. Objectives of the research 56 2.1. Primary objective: 57 -To demonstrate the superiority of a first-line aspiration strategy (ADAPT) during cerebral 58 thrombectomy, compared with first-line stent retriever use in cerebral infarction related to proximal 59 occlusion 60 61 2.2. Secondary objectives: 62 -To compare, between these two strategies of thrombectomy: 63
• the degree of recanalization at the end of the first treatment strategy 64 -treatment by IV thrombolysis if the patient is eligible 116 -initiation of medical products, acts, and methods to prevent or treat the worsening or recurrence of 117 cerebral ischemia 118 -the initiation of products, acts, and methods to prevent or treat general complications related to 119 decubitus or the neurological state of the patient. 120 121
Currently, an increasing number of operators begin the thrombectomy procedure by frontline contact 122 aspiration. This strategy makes it possible either to recanalize the occluded artery, or otherwise to mount a 123 stent retriever (synergistic technique) through the suction catheter in case of failure of the aspiration. 124
However, the effectiveness of this strategy has never been proved. 125
The common practice is therefore variable according to the operator, who can choose to use either 126 aspiration (ADAPT technique) or the stent retriever. In case of failure or operational difficulty, operators 127 can switch from one strategy to another. 128 129
In the ASTER study, thrombectomy is planned for all patients included. Randomization will determine 130 whether aspiration is used in the initial therapeutic strategy. Patients randomized to the ADAPT group will 131 therefore undergo a first distal aspiration. Patients in the "stent retriever" group will not have this initial 132 aspiration. The first aspiration thrombectomy procedure (ADAPT) or stent retriever procedure will be 133 performed according to the recommendations of good practice (a maximum of 3 passes, if necessary, 134 before concluding that the technique has failed, and use of a proximal occlusion balloon in the retriever 135 stent arm). 136
The choice of adjuvant techniques will be left to the operator's discretion. This information will be 137 collected in the FIU. In the event of failure, the rescue procedure is left to the operator's choice, with the 138 aim of guaranteeing the patient the best chances of recanalization, and according to the usual practice of 139 the center. 140 141
The type of device used during thrombectomy will be the one routinely used in the center. The centers 142 participating in the study are thus centers that routinely practice both types of technique. All devices used 143 will be CE marked for this indication. The thrombectomy will be carried out by operators who meet the 144 qualifications required for the accreditation of NRI exercise by HAS 2013, having experience in both 145 techniques. Concurrent treatments for the use of these stents and the option of anesthesia (conscious 146 sedation or general anesthesia) are the usual prescriptions for the routine management of these patients. 147 148 149
Population of the study 150
Patients hospitalized for suspicion of ischemic infarction secondary to an occlusion of the anterior 151 circulation within 6 hours from stroke onset. 152 . 153
Information and non-opposition to patient participation 154
After verification of the inclusion and non-inclusion criteria, the principal investigator or one of his / her 155 collaborators (registered on the delegation of authority log) will explain to the patient the objectives and 156 conduct of the study, using an information form and will seek non-opposition from the patient. 157
Most patients eligible for this research will not be in a state of consciousness allowing comprehension of 158 this information; moreover, the inclusion will be carried out in an emergency context. If the state of 159 consciousness of the patient does not allow this, and in view of the therapeutic urgency, the non-160 opposition of a relative (trusted person if it is present) will be sought so as not to delay the management of 161 the patient. Otherwise, the physician will include the patient according to the inclusion protocol in 162 emergency situations. Once the patient has regained a sufficient state of consciousness, his / her objection 163 to further research and processing of the information collected will be sought. 164
The patient can leave the study at any time on request. Patients not complying with the protocol and 165 patients lost to follow-up will not be excluded from the study. 166 167
Randomization Procedure 168
After checking the inclusion and non-inclusion criteria and the patient's non-opposition, the randomization 169 will be done by computer server, the system automatically assigning the strategy group and the inclusion 170 number. The inclusion will be effective after randomization. The patient will then be permanently assigned 171 to the strategy in question. No specific radiological examination is required in the study. Examinations will be carried out according 208 to the habits of the centers in the current management of this pathology. The imaging data (initial MRI or 209 scanner, thrombectomy procedure, MRI or control scanner) will be evaluated centrally after the patient 210 leaves the hospital, by independent experts, in the absence of treatment and clinical data. 211 212 213 214
Study Withdrawal 215
The patient can leave the study at any time on request. Patients who refuse to participate in the 216 study will be treated as usual. The included patients will not be able to participate simultaneously 217 in another trial. 218 219
Research termination may be decided by the sponsor, in particular in the case of complications 220 (after opinion of the Independent Safety Committee) or in the case of non-inclusion. 221 222 4.5. Project feasibility 223 224
The investigating centers have a recruitment of patients admitted for thrombectomy superior to the 225 recruitment necessary for the study (data of activity on 2014). 226
All investigating centers perform thrombectomy in more than 40 patients per year and have 227 experience in both thrombectomy strategies (ADAPT and Stent retriever All data of the patients meeting the inclusion criteria will be collected anonymously. Patients will be 245 identified by a patient number corresponding to a center number, an inclusion number in the center 246 (chronological order) and the patient's initials (first letter of last and first name). 247 A nominative list of the patients enrolled in the study, with the corresponding patient number , will be kept 248 in each center, stored in the investigator binder, and will be destroyed 15 years after the end of the study. 249 250
The clinical variables from the patient record will be reported on an electronic case report form (eCRF) by 251 the principal investigator, one of his collaborators or a clinical study technician. 252
The imaging files will be anonymized, stored on a CD-ROM and collected for a centralized evaluation. 253 254 5.2. Data analysis 255
All the statistical analyses will be performed independently, by a statistician, blinded to the allocated arm, 256 of the Biostatistics Department of the CHRU of Lille under the responsibility of Professor A. Duhamel. 257
The software used will be SAS version 9.3 or later (SAS Institute Inc, Cary, NC, USA). All statistical tests 258 will be performed with a 2-tailed alpha risk of 5%. No interim analysis will be performed. A detailed 259 statistical analysis plan will be written and finalized prior to the database lock. 260 Baseline characteristics will be described for each arm. Quantitative variables will be presented using 261 mean and standard deviation in cases of Gaussian distribution, or using the median and the interquartile 262 range (i.e. 25th and 75th percentiles) otherwise. The normality of the distributions will be assessed 263 graphically by histograms and using the Shapiro-Wilk test. Qualitative variables will be presented as the 264 frequencies and percentages of each modality. 265
Analyses will be conducted in intention to treat and per-protocol samples (deviations from the protocol 266 will be defined in the detailed statistical analysis plan). 267 268
Primary objective 269
The complete recanalization rate at the end of the thrombectomy procedure will be compared between the 270 two arms using a Chi-Square test. The effect size for the ADAPT strategy (experimental arm) will be 271 calculated in terms of absolute and relative rate difference (experimental arm vs. control) with their 95% 272 confidence intervals. A stratified analysis on the center will be carried out to assess the center effect; the 273 Breslow-Day test will be used to test the interaction between the center and the treatment effect. 274 275
Secondary Objectives 276
The quantitative secondary endpoints will be compared between the two arms using the Student's t test or 277 the Mann-Whitney U test in cases of a non-Gaussian distribution. The qualitative secondary endpoints will 278 be compared between the two arms using the The main objective is to show, in patients with cerebral infarction of the anterior circulation, the 284 superiority of first distal aspiration (ADAPT, experimental arm) to increase the complete recanalization 285 rate at the end of the thrombectomy procedure in comparison with the use of first-line stent retriever 286 approach (control arm). 287
According to the literature, the complete recanalization rate after the use of a first-line stent retriever is 288 estimated between 58% and 72% (MR CLEAN, 2014 ESCAPE, 2015 . A retrospective study conducted at 289
Foch and the Rothschild Foundation hospital found a complete recanalization rate of 70% with the use of 290 first-line stent retriever (± the use of rescue thrombectomy) and a complete recanalization rate of 85% with 291 the use of the ADAPT strategy ((± the rescue thrombectomy) (unpublished data). In terms of effect size, 292 this study showed an increase in the recanalization success rate by 21% with the ADAPT strategy. To 293 demonstrate this effect size, with a two-sided test, an alpha risk of 5% and a power of 90%, 161 patients 294 per arm (322 patients in total) are required. 295 296 6. Regulatory information 297 6.1. Distinction research and care 298
All the medical products, procedures and additional examinations required for the study are prescribed / 299 performed within the framework of the usual care of the patients. No further follow-up visits are 300 required for the study. The only difference with the routine practice is that the choice of an initial 301 aspiration at the beginning of the thrombectomy procedure is conditioned by the randomization and not 302 by the habits of the center and / or the operator. 303 304 6.2. Safety evaluation 305
Description of Safety Assessment Parameters 306 307
Within the framework of a trial evaluating routine care, all medical acts or strategies which are the 308 subject of this study are part of usual practice and are used in accordance with their indications. Any 309 potential adverse events are those associated with the patient's usual care (care-related). 310 311 312
An Independent Oversight Committee (ISC) will be established to ensure the balance of complication rates 313 between each strategy. Data will be blinded to the randomization group (group A and group B). 314
The CSI will meet on a regular basis throughout the study, on its own initiative or at the request of the 315 proponent. It will include Professor Emmanuel Touze, CHU of Caen, Professor Mikael Mazighi, CHU 316 Lariboisière, and Doctor Olivier Detante, CHU Grenoble. 317 318 319
Managing unwanted events 320 321
These are events that may occur during the study period. Monitoring these adverse effects is part of the 322 routine practice within each center. 323
The events observed in the study will be recorded as they occur in the clinical research file, in order to be 324 presented to the CSI. 325 326
The declaration of serious adverse events related to medical devices and administration of medicines must 327 follow the usual reporting circuit provided by the regulations in force in healthcare institutions, with a 328 copy to the study sponsor (by fax to the clinical research unit on 01 48 03 64 30). 329 330 6.3. Access to data and privacy 331
During and after the trial, the data collected and transmitted to the sponsor by the investigators (or any 332 other collaborators in the research) will be codified. In no case, the names of the persons concerned, their 333 address or any other information enabling a direct identification, will be visible. 334 335 336 6.4. Quality control and quality assurance 337
The conduct of the trial in the investigating centers and the management of the subjects will be done in 338 accordance with the Helsinki Declaration and the current Good Clinical Practices. 339
The investigators of each center undertake to receive representatives of the sponsor for quality control and 340 compliance visits, as appropriate. 341 342
Instructions for data collection 343
All information required by the protocol must be recorded on the electronic clinical research file. These 344 data must be collected and recorded as they are obtained and explicitly recorded in the clinical research 345
file . Any missing data should be coded. 346 347
The investigator is responsible for the accuracy, quality and relevance of all data entered. 348 349
Quality control 350
The investigator shall make the documents and individual data strictly necessary for the monitoring, 351 quality control and audit of this research available to the persons responsible for quality control and duly 352 mandated by the sponsor for this purpose.
353
The person (s) mandated by the sponsor will visit each center on a regular basis once the trial has been set 354 up, one or several times during the course of the research, according to the rhythm of the inclusions and at 355 the end of the trial. During these visits, the following elements will be reviewed: 356 -protection and safety of persons, 357 -compliance with the research protocol, the procedures defined therein and the regulatory texts in force, 358 -quality of data collected in the observation booklet: accuracy, missing data, consistency of data with 359 source documents (medical records, appointment books, originals of laboratory results, etc.) 360 -management of possible products and biological sampling. 361
Any visit will give rise to a written monitoring report. 362 363 364 365 366 confidentiality of information relating to experimental treatments, tests, persons who lend themselves to it, 419 in particular as regards their identity and the results obtained. The data collected by these persons during 420 the quality control or audits are then made anonymous. 421 422 Documents and data relating to this research will be archived at the end of the trial by the investigator and 423 the sponsor for a period of 15 years after the end of the study. This indexed archive includes: 424 -Copies of the mandatory CPP notice 425 -The successive versions of the protocol (identified by the version number and version date), 426 -Correspondence letters with the sponsor, 427 -The paper version of the completed and validated observation booklet of each subject included, 428 authenticated (dated and signed) by the investigator 429 -All appendices specific to the study, 430 -The final report of the study from the statistical analysis and the quality control of the study (with copy to 431 the sponsor). 432 -Possible audit certificates carried out during the research 433 -The database which gave rise to the statistical analysis must also be archived by the analyst (paper or 434 computer). 435 436 6.8. Insurance and Scientific Commitment 437 438
Insofar as research is well qualified as routine care research by the requested CPP, which means no 439 additional risk associated with the study, the insurance will be that of the institution responsible for care 440 (Article L. 1142-2). 441 442
Each investigator will undertake to comply with the obligations of the law and conduct the research 443 according to the B.P.C., in accordance with the terms of the Helsinki Declaration in force. To do so, a 444 copy of the scientific commitment dated and signed by the principal investigator of the participating center 445 will be given to the proponent's representative. 446 447 6.9. Rules for Publication 448
Persons who have actually participated in the development of the protocol, its conduct and the drafting of 449 the results will be signatories to the publications. 450
The Rothschild Ophthalmological Foundation will be mentioned as the sponsor of this research. 
